

FACSIMILE TRANSMISSION

To: ASX

Fax: 1900 999 279 Date: November 30, 2005

From: Carolyn Ireland Pages inc. 6 cover:

Re: PXS shareholding

Please advise by facsimile to +61 3 8650 9901 if this transmission failed, was not clear, or was misdirected.

Dear Sir/Madam,

Please refer the attached forms 604 and 605.

porolyn ireland

Yours sincerely,

Carolyn Ireland

Chief Financial Officer

GBS Ventures

Level 5, 71 Collins St

Melbourne, VIC 3000

Australia

Tel (+61 3) 8650 9926

Fax (+61 3) 8650 9901

www.gbsventures.com.au

The information contained in this fax is confidential and intended solely for the attention of the named addressee(s). Unauthorised use, disclosure or copying is strictly prohibited. If you have received this fax in error, please destroy it and notify us immediately.

60:

page 1/2 15July2001

Form 604

Corporations Act 2001 Section 671 B

Notice of change of interests of substantial holder

 To Company Name/Scheme
 Pharmaxis Ltd

 ACN/ARSN
 082 811 630

1. Details of substantial holder(1)

Name Perpetual Trustees Nominees Limited as Trustee of the Australian Bioscience Trust
ACN/ ARSN (if applicable) 000 341 533

There was a change in the interests of the substantial shareholder on The previous notice was given to the company on 11/3/2005

The previous notice was dated 11/3/2005

2. Previous and present voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities (4)	Previous notice		Present notice	
	Person's votes	Voting power (5)	Person's votes	Voting power (5)
Ordinary	16,040,200	11.9%	14,307,220	8.2%
111111111111111111111111111111111111111				

3. Changes in relevant interests

Particulars of each change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company of scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change(5)	Class (6) and number of securities affected	Person's votes affected
30/11/2005	Perpetual Trustees Nominees Limited ACN 000 341 533 as Trustee of the Australian Bioscience Trust	Disposal of shares	\$3,483,915	Ordinary 1,732,980	1,732,980
	GBS Venture Partners Limited ACN 072 515 247 as Manager of the Australian Bioscience Trust	Disposal of shares	\$3,483,915	Ordinary 1,732,980	1,732,980

4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Nature of relevant Interest	Class and number of securities	Person's votes
Nominees Limited ACN 000 341 533 as Trustee of the Australian	Perpetual Trustees Nominees Limited ACN 000 341 533 as Trustee of the Australian Bioscience Trust	Perpetual Trustees Nominees Limited ACN 000 341 533 as Trustee of the Australian Bioscience Trust	Registered holder	Ordinary 14,307,220	14,307,220
Limited ACN 072 515 247 as Manager of the	Limited ACN 072 515 247 as Manager of the	247 as Manager of the	Manager – power to control disposal	Ordinary 14,307,220	14,307,220

5. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association	

6. Addresses

The addresses of persons named in this form are as follows:

Name	Addrass
Perpetual Trustees Nominees Limited ACN 000 341 533 as Trustee of the Australian Bioscience Trust	Level 7, 1 Castlereagh Street, Sydney NSW 2000
GBS Venture Partners Limited ACN 072 515 247 as Manager of the Australian Bioscience Trust	Level 5, 71 Collins Street, Melbourne VIC 3000

Signature

Print name Geoff Brooke Capacity Managing Director

Date 30/11/2005

Sign here

605 page 2/2 15 July 2001

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.
- (2) See the definition of "relevant interest" in sections 609 and 6718(7) of the Corporations Act 2001.
- (3) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (4) Include details of:
 - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 6718(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest retains (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

- (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (8) The voting shares of a company constitute one class unless divided into separate classes.
- (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

305 _r

page 1/2 15July2001

Form 605

Corporations Act 2001 Section 671 B

Notice of ceasing to be a substantial holder

To Company Name/Scheme Pharmaxis Ltd

ACN/ARSN 082 811 630

1. Details of substantial holder(1)

Name GBS Venture Partners Limited as Trustee for the GBS Bioventures II

ACN/ ARSN (if applicable) 072 515 247

The holder ceased to be a substantial shareholder on The previous notice was given to the company on $\frac{30/11/2005}{11/3/2005}$ The previous notice was dated $\frac{30/11/2005}{11/3/2005}$

2. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change(5)	Class (6) and number of securities affected	Person's votes affected
30/11/2005	GBS Venture Partners Ltd as Trustee for the GBS Bioventures II	Disposal of shares	\$1,815,175	902,910	902,910

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Kature of association	

4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
GBS Venture Partners Limited as Trustee for the GBS Bioventures II	Level 5, Harley House, 71 Collins Street, Melbourne Victoria 3000

Signature

Print name Geoff Brooke Capacity Managing Director

Date 30/11/2005

Sign here

605 page 2/2 15 July 2001

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (e.g. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annoxure to the form, if the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.
- (2) See the definition of "relevant interest" in sections 608 and 6718(7) of the Corporations Act 2001.
- (3) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (4) Include details of:
 - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 6718(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular societies to which the qualification applies).
 - See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (5) The voting shares of a company constitute one class unless divided into separate classes.
- (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.